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CYCLOSPORINE (Csi\) is extensively 
metabolized and primarily excreted in 
bile. Renal elimination of CsA is a minor 
pathway of elimination in humans and ani-
mals with only 6% of an administered dose of 
radioactive CsA recoverable from the urine. ' 
In contrast to its poor renal elimination, 59% 
of radioactivity after administration of tri-
tiated CsA to r:lts was recovered in bifc. ' The 
presence of CsA and its metabolites in bile is 
important for several reasons. The immuno-
logic activity and toxicity of Cs;\ llletabulites 
have not becn clucidated, and thus. a 10c11 
effect on the biliary system may be prcsent 
and would be fXlrticubrly important in a liver 
transplant patient. If signilicant ljuantities uf 
an active or toxic substance arc prcscllt in bile. 
enterohepalic recirculation of those com-
pounds might have a measurable pharmaco-
logical elfect. finally. other drugs and dis-
eases that inlluence cyclosporine metabolism 
could preferentially produce pharmacologi-
cally inactive or toxic meta bol i tes. 
This articlc reviews our quantitative work 
with CsA in bile. describes our qualitati\'e 
work with Cs,\ metabolites in bilc. and dis-
cusses other currcntly Jlublishcd information 
on CsA metabulites in human bilc. 
PATIENTS AND METHODS 
Qualllitatil'e Stlldies 
A complete d~scription of our paticnts :lnd methods has 
been published previously,2 Bile was collected during 18 
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studies from 13 patients with a T-tube in their common 
bile ducts, Twd,'c patients were receiving CsA following 
orthotopic liver transplantation. and one patient with liver 
disease was given a single intravenous (IV) CsA dose. Bile 
was collected over an 8- to 24-hour interval and was 
anaiv7cd for unchanged Cs:\ by high-performance liquid 
chromatography (HPLC). :\ radioimmunoassay (RIA) 
procedure] was used to det~ct total quantities of CsA plus 
metabolitcs reactive with the RIA (abbreviated as CsT 
for clarity), Patients were arbitrarily divided into those 
haling norlll:ll hepatic function (total serum bilirubin less 
than I Illgjdl) and those With poor function (total serum 
bilirubin gre:ller th:lll 1 mg/dL) for comparison. 
QUi//itarin'Stlldies 
PUllkd bile frolll a single liver transplant patient was 
colkctnl o\'er two days [rom J T-tube in the common bile 
ducl. Three-milliliter aliqu()ts of bile were exlractcd with 
diethvl ether :Iccordil\[! l<l the blood extr:lction procedure 
of S:twchuk and Cartier.' The extracted material was 
rcconstitukd with mobile ph:tse and injected onto the 
II PI.C column. The III'LC system was similar to a 
rrcvi(lus ,kscrirtion' excert that a (,()-minutc gradient of 
acetonitriic·\\ater was used :JS the mobile phase. 
\Iajor re:lks were colkcted. mobile phase was 
removed. Jnd the residue obtained was analyzed by 
desorptiun chemical ionization mass srectromctry using 
:In Extrcl \1,)del ·100-21) m.bS srectrorneter (Extrcl Cor-
rnratioll, Pittshllr,t:h), 
Cyclosr')rtn (j (CsGl. ~O Ilg. was added during one 
c.\traction rrllcedure as an internal standard to provide an 
eSlim:~t~ d[ thc amount l)f each ll1~t:Jb"litc in the pooled 
bile ""l1ric. The :If\::lS "r th~' ll1~t:lb<)lite peaks were 
COlllr':lfl:d \\ itlt the pc:!k ar~a (If es(i to proviue an 
estil11ale reiative to the amounl of esG in the sample. 
RESULTS 
;\ wide range of conccntrations of CsA 
were observed in the bile of liver transplant 
patients. Thc CsA concentration in bile deter-
mined by HPLC ranged from 32 ng/mL in 
the p~lticnt with severe liver disease to 5,212 
ng/lllL in a transplant patient with normal 
hepatic function. Table I lists the mean con-
centration~ of Cs,\ in bile mcasured by HPLC 
for llic nurmal and poor liver function 
r.lticflts. Tile CsT conccntralion in bile mea-
sured by R 1,\ r~lnged from 18 to 36 times 
higher lInn the Cs!\ concentration, In our 
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Table 1. CsA in Bile Measured by HPLC 
Liver Function 
Group 
Normal (n - 3) 
Poor (n - 15) 
Average Bile 
Volume 
(mLjh) 
24.1 
5.5 
subjects, the fa tio of CsT:CsA ranged from 
23:1 to 39: 1 with a mean of 30: 1. Table 2 
presents the estimated percentage of an 
absorbed CsA dose excreted in bile and dem-
onstrates that CsA represents less than 4.% of 
the measured RIA-reactive compounds in 
bile. Since the total volume of bile docs not 
drain from the T-tube. the predicted row in 
Table 2 adjusts the volullle of bil<.:: to 1 Lj 
day. 
While the relationship between blood and 
bile CsA is not always consistent, CsA in bile 
peaks several huurs following a CsA d()se. 
Figure 1 demonstrates the blood and bile CsA 
concentrations following a CsA dose. 
Diethyl ether extraction of bile produced an 
HPLC chromatogram with seven major peaks 
having retention times shorter than CsA (Fig-
ure 2). Cyclosporine and its metabolites 
produccd a characteristic mass spectral fr~lg­
mentation pattern under methane chemical 
ionization conditions. The metabolites that 
were analyzed and CsA produced a 4uasimo-
lecular ion and an M + 29 adduct ion. The 
mass spectr;) also dcrnunstrated a loss uf a 
seven-carbon fra!2l11ent with an atomic mass 
unit of 112, ex(ep~ for peaks 1,4, and 6, which 
lost a mass unit of In. 
Peak I produced an i\! +. I ion at 1,235, 
indicating two hvdroxyl substitutions and con-
sidered to be th~ equivalent of MS described 
--2able 2. CsA in Bile Measured by RIA and HPLC 
Percentage of Absorbed Dose 
Excreted in BIle 
Patients HPLC RIA ---~--------------------------------~ Poor liver function" 0.12 
Normal liver function" 0.85 
Predicted in normal 
~r functiont 1.46 
• Amount recovered from T -tube. 
tAmOunt predIcted In 1 Liday of bile. 
3.6 
25.5 
43.8 
Average Bile HPLC 
Concentration 
InglmLi 
3288 
1379 
Average Amount of 
CsA in Bile 
!J.tg!h) 
79.2 
7.6 
by Maurer et a1.6 Peak 3 produced an M + 1 
ion at 1,205, indicating metabolic loss of a 
methyl group and the addition of a hydroxyl 
substitution. Peak 3 has the equivalent mass 
of Maurer et aI's M 13.6 
Additional evidence of peak identity was 
provided by injection of previously isolated 
and identified metabolites (kindly provided by 
G. Maurer). Injection of Maurer et aI's M 17, 
MI, and \121 produced identical retention 
times to peaks 4,5, and 7, respectively. Peaks 
4, 5, 6, and 7 produced identic;)l retention 
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Fig 1. Cyclosporine blood and bile concentration v 
time in an orthotopic liver transpla;lt patient. 
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times to M!7, MI. r-..1!8. <lnd M2! on a 
sep<lrate chromatographic systcm (T. Rosano. 
personal communication). 
By comparison of peak areas in the pooled 
bile sample, the seven major peaks were 1.5 to 
4.0 times the peak area of CsA. 
DISCUSSION 
Biliary excretion ofCs!\. and its metabolites 
is the major route of drug elimin<ltion. While 
substances in bile can be reabsorbed and 
recirculated. our study shows that less than 
2% of a dose of Cs!\. appears in the bile even in 
the presence of normal liver function. The 
reabsorption of the parent compound is there-
fore inconsequential in discussions of a second 
peak concentration of CsT measured by RIA? 
or late peaks of immunosuppressive activity.8 
Cyclosporine metabolites are present in bile 
in large concentrations. Even though CsA 
metabolites only selectively cross-react with 
the RlA,9 concentrations of CsT approaching 
100,000 ng/mL have been measured in bile.) 
Table 2 would indicate that only about one 
half of Cs!\.-related compounds can be mea-
sured by the RIA. These Cs!\ metabolites 
would also have the opportunity to be 
reabsorbed and arc therefore a potential 
explanation for late increases in serum immu-
nosuppressive activity or for the disparity 
4 7 
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Fig 2. HPLC chromato-
gram for an ether extract of 
bile. The patient received CsA; 
esG was added to the bile as an 
internal standard. Peaks 4, 5, 6, 
and 7 correspond to M17. Ml, 
M1B, and M21 isolated by 
Maurer et al.8 
occasional! y observed bet wecn Cs;\ blood 
concentrations and clinical elfect. 
Two major hydroxylated metabolites. M 17 
and \118. appear to express less immunosup-
pressive actirity than CsA.'O More recent 
studies have suggested thal the concentrations 
of M 17 that arc achieved in the blood of renal 
transplant patients may be as active in mixed 
Iymphocytc cultures as is CSA.'I Both M 17 
and \118, idcntilied as peaks 4 and 6 in our 
studics. arc found in bile and will most likely 
be present in concentrations exceeding blood 
concen tra tions. Thei r i mmunosu ppressive ef-
fects locally on the biliary tract would be 
additi\c to that of CsA. While Cs!\. appears in 
bile in high concentrations in patients with 
normal liver function. the additive local 
immunosuppressant properties of the metabo-
lites may be critical in patients with impaired 
li\'er function (who have the lowest CsA bile 
concentrations) duc to rejection or technical 
complications following livcr transplantation. 
Two separate groups of cther-extractable 
(sA metabolites arc present in bile: those that 
are very nonpolar (peaks 4 to 7) and those thaI 
arc slightly more polar (peaks 1 to 3). No 
single metabolite appears to predominate, and 
other more-polar mctabolites might be identi-
fied using dilferent extraction tcchnqiues. For 
cxaml,!e. a carboxylic acid mctablliitc has 
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been isolated from an ethyl acetate extraction 
of rabbit and human bile. 12 The more-polar 
metabolites are less likely to cross lipoprotein 
membranes and express activity. For example, 
while there is general agreement that Maurer 
et aI's M 17 possesses some minor pharmaco-
logic activity, the addition of another polar 
group (hyroxyl) to form M8 makes the com-
d · . II poun mactlve. 
Proper quantitation of CsA metabolites in 
blood or bile is important in understanding 
their potential pharmacologic or toxic()logic 
effects. Hartman et al 12 claim that the carbox-
ylic acid metabolite is the major metabolite 
without quantitating other nonpolar CsA 
metabolites. Another recent report makt:s 
some interesting obsavations on the immuno-
logical activity of diethyl etht:r-soluble iso-
lates from blood. bile, and urine 13 but provides 
only an imprecise metabolite quantitation of 
the RIA. Precise quantitation of metabolites 
in blood, bile, and urine by H PLC must be 
available for a meaningful assessment of the 
pharmacologic role of CsA metabolites. In 
this manner, quantitation of the impact of 
drug-metabolite interactions, such as has 
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already been reported for phenytoin,14 can be 
predicted. 
SUMMARY 
Quantitative and quaHtative studies of 
cyclosporine and its metabolites were per-
formed on human bile from liver transplant 
and liver disease patients. The concentration 
of CsA in bile is higher in patients with 
normal liver function than in those with poor 
liver function but in neither case could 
accoun t for more than 2'I of a n absorbed dose 
of CsA. Although concentrations of CsA plus 
metabolites in bile measured by RIA were 18 
to 36 times higher than H PLC concentrations, 
th<.:y ac<.:ounteu for less than 50% of an 
absorbed CsA dose. By means of mass spec-
trometry and H PLC retention times of known 
metabolites, peaks equivalent to the previ-
ously isolated CsA Mll, 1\1 13, M 17, M 1, M 18, 
and :-'121 of ~faurer et al were found in the 
ether extracts of bile. Future studies should 
not only concent ra te on the pha rmacologic 
and toxicologic e1fects of the metabolites but 
should also accurately quantitate these com-
pounds in blood, plasma, urine, and bile. 
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